Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical Stage

Polyrizon Ltd. (NASDAQ: PLRZ) has enrolled its first patient in a U.S. clinical study for NASARIX (PL-14), an investigational Allergy Blocker aimed at treating seasonal allergic rhinitis. This milestone signifies Polyrizon's transition into a clinical-stage company, focusing on the efficacy, safety, and tolerability of its product. The trial marks a key development in the company's strategy to advance its innovative intranasal hydrogels.